Your browser doesn't support javascript.
loading
Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose
Rossana Elena Chahla; Rodrigo Hernan Tomas-Grau; Silvia Ines Cazorla; Diego Ploper; Esteban Vera Pingitore; Monica Aguilar Lopez; Patricia Aznar VII; Maria Elena Alcorta; Eva Maria del Mar Velez; Agustin Stagnetto; Cesar Luis Avila; Carolina Maldonado Galdeano; Sergio Benjamin Socias; Dar Heinze; Silvia Adriana Navarro; Conrado Llapur; Dardo Costas; Isolina Flores; Gabriela Apfelbaum; Raul Mostoslavsky; Gustavo Mostoslavsky; Gabriela del Valle Perdigon; Rosana Chehin.
Afiliación
  • Rossana Elena Chahla; Tucuman Public Healthcare Administration (SIPROSA)
  • Rodrigo Hernan Tomas-Grau; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman Argentina
  • Silvia Ines Cazorla; Reference Center for Lactobacilli. CERELA (CONICET). Tucuman, Argentina
  • Diego Ploper; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman Argentina
  • Esteban Vera Pingitore; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman Argentina
  • Monica Aguilar Lopez; Nestor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA). Tucuman, Argentina.
  • Patricia Aznar VII; Nestor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA). Tucuman, Argentina.
  • Maria Elena Alcorta; Nestor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA). Tucuman, Argentina.
  • Eva Maria del Mar Velez; Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucuman. Tucuman.
  • Agustin Stagnetto; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman Argentina
  • Cesar Luis Avila; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman Argentina
  • Carolina Maldonado Galdeano; Reference Center for Lactobacilli. CERELA (CONICET). Tucuman, Argentina
  • Sergio Benjamin Socias; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman Argentina
  • Dar Heinze; Section of Gastroenterology, Department of Medicine, Center for Regenerative Medicine (CReM), Boston University School of Medicine, Boston, USA
  • Silvia Adriana Navarro; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman Argentina
  • Conrado Llapur; Nestor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA). Tucuman, Argentina.
  • Dardo Costas; Nestor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA). Tucuman, Argentina.
  • Isolina Flores; Nestor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA). Tucuman, Argentina.
  • Gabriela Apfelbaum; School of Medicine. Universidad Nacional de Tucuman. Tucuman. Argentina
  • Raul Mostoslavsky; The Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA
  • Gustavo Mostoslavsky; Section of Gastroenterology, Department of Medicine, Center for Regenerative Medicine (CReM), Boston University School of Medicine, Boston, USA
  • Gabriela del Valle Perdigon; Reference Center for Lactobacilli. CERELA (CONICET). Tucuman, Argentina
  • Rosana Chehin; Institute of Applied Molecular and Cellular Medicine. IMMCA (UNT-CONICET-SIPROSA). Tucuman ArgentinaCONICET
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21253039
ABSTRACT
We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucuman, Argentina, with previous COVID-19 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of available doses. One-Sentence SummaryFirst vaccine dose in subjects with prior COVID19 elicits a higher antibody response than two doses in uninfected individuals
Licencia
cc_no
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint